Press release
ICRC-Weyer Enhance Medical Data Management Services
ICRC-Weyer Logo
“The medical review service contains the review of clinical databases by well-trained medical staff which take place during study conduct or prior to analysis.” says Johann Daniel Weyer, a Managing Director at ICRC-Weyer GmbH. “The medical specialists check and discover medical inconsistencies or implausibilities in the data, providing assistance to study teams and allowing decision makers to reduce potential hazards or provide support in (re)interpreting safety and efficacy data on projects.”
ICRC-Weyer has a broad network of medical experts that specialise in various fields. Together with the supervision from the medical data management services team and their purpose-built tools and custom procedures, the company is able to provide services across a vast range of therapeutic areas.
Medical data management works closely with other departments at ICRC-Weyer, including pharmacovigilance and clinical data management.
ICRC-Weyer is an established all phase contract research organization (CRO) based in Berlin, Germany. The company was founded in 1993 by Prof. Dr. Geerd Weyer and offers services ranging from pre-clinical through to phase IV clinical trials. ICRC-Weyer provides complete turnkey solutions including data management, monitoring and medical review services for all stages of the clinical development process.
ICRC-Weyer is involved in several global clinical trials and – through collaboration with strong partners – has established a position at the forefront of the latest developments in the world of clinical research. ICRC-Weyer can support clinical projects at any stage from initial trial inception through to regulatory submission.
The experienced team of ICRC-Weyer has substantial expertise in the various divisions of clinical research, which enables the company to offer services from preclinical to phase I-IV, health claim and post-marketing studies for pharmaceutical, biotech and nutrition companies.
ICRC-Weyer provides services either separately or as synergistic multi-service packages. These Services include Biostatistics, Clinical/Medical Data Management, Independent Expert Medical Review, Medical Writing, Clinical Monitoring, Pharmacovigilance, Regulatory Services, Scientific Consulting and Study Conduct in cooperation with a Phase I and II Unit.
ICRC-Weyer has special expertise in Nutrition, CDISC Data Standards and Medical Review.
ICRC-Weyer GmbH
Boelschestrasse 2, 12587 Berlin, Germany
Phone: +49 30 403937-0
E-mail: daniel.weyer@icrc-weyer.com
www.icrc-weyer.com
Press Contact: Johann Daniel Weyer, Managing Director
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ICRC-Weyer Enhance Medical Data Management Services here
News-ID: 220796 • Views: …
More Releases from ICRC-Weyer GmbH
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors.
An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors.
‘A large…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
More Releases for Weyer
Global Neonatal Incubator Market - AHT, Natus Medical, Weyer GmbH, Fanem
The report that is written on the title Neonatal Incubator Market covers all across the globe, recently added to the repository of Market Research, is titled ‘Global Neonatal Incubator Market 2017’. The research report analyses the historical as well as present performance of the worldwide Neonatal Incubator industry, and makes predictions on the future status of Neonatal Incubator market on the basis of this analysis.
An infant incubator is a…
ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process.
The decision to form MEDIS Research Group came as a reaction to a shift in the market towards…
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing.
‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We…
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments.
The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives…
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio.
‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted…
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in…
